177Lu- DOTA-TATE treatment for advanced gastrointestinal neuroendocrine tumor with refractory carcinoid syndrome.

Lutathera (lutetium Lu 177 dotatate) - Novartis

177Lu- DOTA-TATE treatment for advanced gastrointestinal neuroendocrine tumor with refractory carcinoid syndrome. (PubMed, Endokrynol Pol) - Oct 20, 2026 - No abstract available
Journal • Carcinoid Syndrome • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor

http://www.ncbi.nlm.nih.gov/pubmed/42895232

Anhelli Syrenicz; Anna Brzeska; Karol Sagan; Marta Malarz; Martyna Patalong-Wójcik

Oct 20, 2026